These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32053962)

  • 1. Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.
    Souto EB; Silva GF; Dias-Ferreira J; Zielinska A; Ventura F; Durazzo A; Lucarini M; Novellino E; Santini A
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32053962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanopharmaceutics: Part II-Production Scales and Clinically Compliant Production Methods.
    Souto EB; Silva GF; Dias-Ferreira J; Zielinska A; Ventura F; Durazzo A; Lucarini M; Novellino E; Santini A
    Nanomaterials (Basel); 2020 Mar; 10(3):. PubMed ID: 32143286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects.
    Agarwal V; Bajpai M; Sharma A
    Recent Pat Drug Deliv Formul; 2018; 12(1):40-52. PubMed ID: 29303083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
    Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
    Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good Manufacturing Practice (GMP) Compliance for Phage Therapy Medicinal Products.
    Bretaudeau L; Tremblais K; Aubrit F; Meichenin M; Arnaud I
    Front Microbiol; 2020; 11():1161. PubMed ID: 32582101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good manufacturing practice for immunological veterinary medicinal products.
    Todd JI
    Rev Sci Tech; 2007 Apr; 26(1):135-45. PubMed ID: 17633298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Regulatory Trends in Pharmaceutical Manufacturing and their Impact on the Industry.
    Tabersky D; Woelfle M; Ruess JA; Brem S; Brombacher S
    Chimia (Aarau); 2018 Mar; 72(3):146-150. PubMed ID: 29631666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GMP-Grade Methods for Cardiac Progenitor Cells: Cell Bank Production and Quality Control.
    Andriolo G; Provasi E; Brambilla A; Lo Cicero V; Soncin S; Barile L; Turchetto L; Radrizzani M
    Methods Mol Biol; 2021; 2286():131-166. PubMed ID: 33381854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good manufacturing practice: the role of local manufacturers and competent authorities.
    Tomić S; Filipović Sučić A; Ilić Martinac A
    Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of PRP Manufacturing Requirements & European Regulatory Frameworks: Practical Tools for the Appropriate Implementation of PRP Therapies in Musculoskeletal Regenerative Medicine.
    Sebbagh P; Cannone A; Gremion G; Gremeaux V; Raffoul W; Hirt-Burri N; Michetti M; Abdel-Sayed P; Laurent A; Wardé N; Applegate LA
    Bioengineering (Basel); 2023 Feb; 10(3):. PubMed ID: 36978683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaceutical product quality control and good manufacturing practices].
    Hiyama Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanopharmaceuticals (part 2): products in the pipeline.
    Weissig V; Guzman-Villanueva D
    Int J Nanomedicine; 2015; 10():1245-57. PubMed ID: 25709446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanopharmaceuticals: Tiny challenges for the environmental risk assessment of pharmaceuticals.
    Berkner S; Schwirn K; Voelker D
    Environ Toxicol Chem; 2016 Apr; 35(4):780-7. PubMed ID: 25931425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for good practices in biomedical technology.
    Koech DK
    Afr J Health Sci; 1996 Feb; 3(1):1. PubMed ID: 17451285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturing of biodrugs: need for harmonization in regulatory standards.
    Sahoo N; Choudhury K; Manchikanti P
    BioDrugs; 2009; 23(4):217-29. PubMed ID: 19697964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
    Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
    Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.